 |
|
|
| |
PEARL-II: RANDOMIZED PHASE 3 TRIAL OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333 WITH OR WITHOUT RIBAVIRIN IN HEPATITIS C VIRUS GENOTYPE 1B-INFECTED, TREATMENT-EXPERIENCED PATIENTS
|
| |
| |
Reported by Jules Levin
DDW - Digestive Disease Week 2014, Chicago, IL, United States, 4-6 May 2014
Pietro Andreone, Massimo G Colombo, Jeffrey V Enejosa, Iftihar Koksal,
Peter Ferenci, Andreas Maieron, Beat Müllhaupt, Yves Horsmans, Ola Weiland,
Henk W Reesink, Lino Rodrigues-Jr, Y Bonnie Hu, Thomas Podsadecki
On behalf of the PEARL-II Investigators
|
| |
|
|
|
|
|
